Equities Analysts Set Expectations for Diplomat Pharmacy Inc’s FY2018 Earnings (DPLO)

Diplomat Pharmacy Inc (NYSE:DPLO) – Research analysts at William Blair cut their FY2018 earnings estimates for Diplomat Pharmacy in a research report issued to clients and investors on Wednesday, November 7th. William Blair analyst J. Kreger now anticipates that the company will post earnings of $0.77 per share for the year, down from their prior estimate of $0.82. William Blair also issued estimates for Diplomat Pharmacy’s Q4 2018 earnings at $0.20 EPS, Q1 2019 earnings at $0.23 EPS, Q2 2019 earnings at $0.23 EPS, Q3 2019 earnings at $0.21 EPS, Q4 2019 earnings at $0.23 EPS and FY2019 earnings at $0.91 EPS.

Diplomat Pharmacy (NYSE:DPLO) last announced its earnings results on Tuesday, November 6th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.21). The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.42 billion. Diplomat Pharmacy had a net margin of 0.04% and a return on equity of 5.31%. The firm’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.01 earnings per share.

DPLO has been the topic of several other reports. ValuEngine cut shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Tuesday, November 6th. Robert W. Baird cut shares of Diplomat Pharmacy from a “neutral” rating to an “underperform” rating and decreased their target price for the company from $22.00 to $10.00 in a research report on Wednesday. Zacks Investment Research cut shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Tuesday, October 23rd. Mizuho decreased their target price on shares of Diplomat Pharmacy to $18.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, Wells Fargo & Co decreased their target price on shares of Diplomat Pharmacy from $23.00 to $16.00 and set a “market perform” rating on the stock in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the stock. Diplomat Pharmacy presently has a consensus rating of “Hold” and an average price target of $24.50.

Shares of NYSE DPLO opened at $16.09 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.63 and a current ratio of 0.95. The stock has a market cap of $1.10 billion, a PE ratio of 19.15 and a beta of 0.95. Diplomat Pharmacy has a 12-month low of $13.31 and a 12-month high of $28.74.

In related news, Director Philip R. Hagerman sold 57,500 shares of the company’s stock in a transaction dated Tuesday, September 11th. The shares were sold at an average price of $19.21, for a total transaction of $1,104,575.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Philip R. Hagerman sold 209,367 shares of the company’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $19.07, for a total transaction of $3,992,628.69. The disclosure for this sale can be found here. Corporate insiders own 24.70% of the company’s stock.

A number of hedge funds have recently modified their holdings of DPLO. FMR LLC grew its stake in Diplomat Pharmacy by 154.4% in the 2nd quarter. FMR LLC now owns 2,798,440 shares of the company’s stock worth $71,528,000 after acquiring an additional 1,698,341 shares in the last quarter. Frontier Capital Management Co. LLC grew its stake in Diplomat Pharmacy by 84.1% in the 3rd quarter. Frontier Capital Management Co. LLC now owns 3,535,217 shares of the company’s stock worth $68,619,000 after acquiring an additional 1,614,645 shares in the last quarter. Janus Henderson Group PLC grew its stake in Diplomat Pharmacy by 30.7% in the 2nd quarter. Janus Henderson Group PLC now owns 5,385,168 shares of the company’s stock worth $137,645,000 after acquiring an additional 1,265,271 shares in the last quarter. Victory Capital Management Inc. grew its stake in Diplomat Pharmacy by 17,568.5% in the 2nd quarter. Victory Capital Management Inc. now owns 1,239,442 shares of the company’s stock worth $31,679,000 after acquiring an additional 1,232,427 shares in the last quarter. Finally, BlackRock Inc. grew its stake in Diplomat Pharmacy by 17.0% in the 3rd quarter. BlackRock Inc. now owns 8,464,251 shares of the company’s stock worth $164,292,000 after acquiring an additional 1,228,490 shares in the last quarter. Institutional investors and hedge funds own 82.05% of the company’s stock.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

See Also: What is Cost of Debt?

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply